Organization | National Institute for Public Health and the Environment, RIVM, Holland

National Institute for Public Health and the Environment, RIVM, Holland Report issue

Government Phase 2 Phase 4

Founded: Utrecht Netherlands (1909)

Organization Overview

First Clinical Trial

2009

NCT00815282

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

National Institute for Public Health and the Environment (RIVM)

Active Ingredients

Drugs in Phase 4 Trials (10)

acellular pertussis vaccine (ACEL-IMUNE\T) (1 trial)

attenuated measles vaccine - Edmonston strain (rubeovax) (2 trials)

azithromycin (zithromax) (1 trial)

diphtheria, tetanus and whole cell pertussis vaccine (Boostrix) (2 trials)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

hpv 16/18 vaccine (Cervarix) (2 trials)

inactivated influenza vaccine (1 trial)

oseltamivir (tamiflu) (1 trial)

tetanus toxoid (1 trial)

whole-cell pertussis vaccine (1 trial)

Drugs in Phase 2 Trials (3)

Inactivated polio virus - Enhanced (IPOL) (1 trial)

live oral poliovirus type 1, 2 and 3 (Trivalent oral polio vaccine - Sabin) (1 trial)

rifampin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Arthritis, Juvenile (Phase 4)

Autoimmune Diseases (Phase 4)

Dermatomyositis (Phase 4)

Influenza, Human (Phase 4)

Lupus Erythematosus, Systemic (Phase 4)

Measles (Phase 4)

Papillomavirus Infections (Phase 4)

Poliomyelitis (Phase 2)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Whooping Cough (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 13